Back to News
Market Impact: 0.2
Helus Pharma, Formerly Cybin Inc., Highlights Clinical Program Advancements at October 21, 2026 Investor Presentation
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Helus Pharma Inc. (formerly Cybin Inc.) outlined progress in its lead clinical programs, HLP003 and HLP004, at an investor presentation on October 21, 2026. The company reiterated a topline data readout from its APPROACH Phase 3 study, but the supplied article text cuts off before identifying the study program or giving timing and results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
HELP0.30
More News
- SK Hynix shares slide after chipmaker scraps Solidigm IPO plans
- Apple’s iPhone Duo Hits Stores in Face of Short Supply and High Demand
- OpenAI nears up to $30 billion funding round at $1.25 trillion valuation led by UAE investors
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- SpaceX records $561 million investment gain from stake in Elon Musk's Boring Co.